Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)
about
Targeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member cytokines with selectable target spectrum.Covalent docking of large libraries for the discovery of chemical probesTofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).Chiral kinase inhibitors.Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production.Enantioselective Transesterification Catalysis by Nanosized Serine Protease Subtilisin Carlsberg Particles in Tetrahydrofuran.Selective JAK inhibitors in development for rheumatoid arthritis.Intracellular signal pathways: potential for therapies.CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSPNovel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres.Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedbackJAK Kinases in Health and Disease: An UpdateSpecific Jak3 Downregulation in Lymphocytes Impairs γc Cytokine Signal Transduction and Alleviates Antigen-driven Inflammation In VivoThe use of structural biology in Janus kinase targeted drug discovery.Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinasesJanus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.New JAK2 inhibitors for myeloproliferative neoplasms.Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?Targeting kinases for the treatment of inflammatory diseases.JAK2 inhibitors in the treatment of myeloproliferative neoplasms.The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects.Tyrosine kinases in rheumatoid arthritis.Application of chemical biology in target identification and drug discovery.Tofacitinib for the treatment of ulcerative colitis.CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes.Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitorsDesign and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects.Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.Tofacitinib in psoriatic arthritis.The role of the JAK/STAT signal pathway in rheumatoid arthritis.Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology
P2860
Q27312407-BD99E2A4-BF83-444F-9557-C816CEA17E50Q28250319-B1B05E0A-77F7-484A-8111-D444B7722D3BQ30313903-B348C2D2-E4CE-412B-B562-D70DE395C6F9Q33811207-1C707AD1-283D-4B3B-8C15-D3F335493338Q33932779-6059317A-EC32-413C-85FD-314CB0817A8FQ34007875-258C28CA-FF6A-4882-9007-7E1B919596BDQ34015347-EBB3A6AF-AB5D-42A9-A9E4-F2702B494A5CQ34419615-AA1BEE6A-41E2-40C7-8634-FD3686980602Q34551138-908AB65A-B0F1-4D10-A63E-15463A4689E2Q34667760-3DA26ADA-CA45-499E-A336-FC8003F5F25FQ35228409-A3624585-CFA8-472E-8146-89B8E8BF0B36Q36238033-1808A54E-A4C0-4FF5-91CB-8449DB364ADEQ36285745-25754453-7477-4403-83ED-353F1BAC06AAQ36299372-E1CD2394-97B2-4DBC-8079-ADEBB6FA0ABCQ37206115-1039882B-62B7-4310-8AE8-0D7CA3037E3CQ37687519-02AF0495-17E3-45CE-B2AB-D6B984DB6ECCQ37833893-D1504614-D9E9-4204-8B00-E78D8D2B3A9AQ37869152-80BD9CEB-EC3F-4A20-B9B1-F6167CC160C3Q37998574-B605A7DF-5630-4648-B85D-1FF482F0CD59Q38028572-7F09628F-6874-452A-958E-C63E28596BDAQ38044736-8EF3BC55-E093-4E63-92B0-F7EC53A5DB87Q38068109-01000089-C586-4F99-9A4F-10633220F38CQ38081267-0CD9005A-6C6C-47BD-BC8D-907777952B83Q38100790-B3087513-E904-49FB-85DA-630495450FD0Q38167009-990985F9-1983-44E4-9A93-9CBA07B28887Q38217595-AFE81F61-9F4A-410C-9BCE-C7EC66D7B074Q38366902-3E12BAEF-7F89-45E3-A9E9-E63C9BE853EFQ38560888-1F945594-6F3A-427B-9EF4-D564BD287CE2Q38833865-AFF976D7-8F98-4DBD-8445-C07BDFA0C4B4Q39185214-C38DF203-C6B3-4415-9848-BDB827A3C055Q41893567-FC26B761-EC32-4C64-AA60-29FEC16125B5Q45332740-716273F6-E0E5-4C82-8B5B-FE97FEBAE1F3Q50900106-98B63ED3-6797-41B9-B6E7-96002F74C9E8Q52626728-3030EF49-F742-424C-8355-1FB2EED8DB0BQ53791793-1CA5FF78-42CB-4449-B0E8-EB54DB667A0EQ54988148-C721C914-293E-4726-B654-A8D6A00207E4Q55487787-86467F1B-4832-45DC-A262-E24FE25435FDQ58779800-8406388C-6189-4CDF-BECE-1A7E366C5CC2
P2860
Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Examining the chirality, confo ...... oxopropanenitrile (CP-690,550)
@en
Examining the chirality, confo ...... xopropanenitrile (CP-690,550).
@nl
type
label
Examining the chirality, confo ...... oxopropanenitrile (CP-690,550)
@en
Examining the chirality, confo ...... xopropanenitrile (CP-690,550).
@nl
prefLabel
Examining the chirality, confo ...... oxopropanenitrile (CP-690,550)
@en
Examining the chirality, confo ...... xopropanenitrile (CP-690,550).
@nl
P2093
P2860
P356
P1476
Examining the chirality, confo ...... oxopropanenitrile (CP-690,550)
@en
P2093
Craig J Thomas
Dac-Trung Nguyen
Eric H Liu
Francesca Deflorian
Jeremy Smith
Jian-kang Jiang
John J O'Shea
Kamran Ghoreschi
Marko Pesu
Melissa Perreira
P2860
P304
P356
10.1021/JM801142B
P407
P577
2008-12-01T00:00:00Z